Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epigenetic Oncological Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for EED drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | EED Recombinant Protein (WD40 Domain / Full-Length WT & Mutants) High purity (>95%), Endotoxin Controlled. Sequence Verified. |
View EED Products |
| Gene Delivery | EED Promise-ORF / Lentivirus Full-length ORF for stable cell lines and target engagement assays. |
View EED Products |
| Benchmark Ab | Anti-EED Recombinant Antibody Recombinant positive control for IP, Western Blot, and ChIP assays. |
View EED Products |
| Validator | EED siRNA Set For target knockdown and specificity validation. |
View EED Products |
| Related Target A | EZH2 Catalytic core of the PRC2 complex; synergistic target for dual-inhibition strategies. |
View EZH2 Products |
| Related Target B | SUZ12 Essential structural scaffolding partner of the PRC2 complex, critical for complex assembly validation. |
View SUZ12 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allosteric pocket binding verification | Highly stable EED WD40 domain proteins expressed in insect cells, preserving native folding. |
| Screening against drug-resistant mutations | EED Mutant Panel (e.g., Y358N, R302G) strictly verified by sequencing and mass spectrometry. |
| Lack of Controls | Clinical Benchmark Antibodies and reference inhibitors included |
| False Positives | Validated siRNA included for phenotypic and target-specificity checks |
Live EED R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for EED therapeutics is intensifying, with major players shifting focus from traditional EZH2 catalytic inhibitors to EED allosteric inhibitors and EED-targeting PROTACs (Proteolysis Targeting Chimeras). As first-generation therapies reach the clinic, the next wave of R&D is targeting EZH2-mutant resistant cancers and advanced solid tumors by disrupting the entire PRC2 complex assembly.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Small Molecule | Novartis (MAK683), AbbVie (A-395) | Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma | Allosteric site binding assays (Need high-purity EED WD40 domain) |
| PROTAC / Degrader | Arvinas, Boehringer Ingelheim | Prostate Cancer, Triple-Negative Breast Cancer (TNBC) | Target engagement & ternary complex assays (Need WT EED and EZH2/SUZ12 proteins) |
| Combination Therapy | Academic Consortia, Biotech Startups | EZH2-inhibitor resistant hematological malignancies | Mutant screening panels (Need EED Y358N and other resistant mutant proteins) |